Alkermes plc ALKS
45.89 USD +0.20 (+0.44%)
At closeNov 4, 2026, 5:30 PM EST
45.89 0.00 0.00%
After hours · Nov 4, 5:30 PM ET
44.58 Day range 47.01
27.00 52-week range 55.67
- YTD
- +64.01%
- 1 year
- +51.00%
News
benzinga.com RBC Capital Maintains Outperform on Alkermes, Raises Price Target to $57 RBC Capital analyst Leonid Timashev maintains Alkermes (NASDAQ:ALKS) with a Outperform and raises the price target from $56 to $57.- benzinga.com Wells Fargo Maintains Overweight on Alkermes, Raises Price Target to $68 Wells Fargo analyst Benjamin Burnett maintains Alkermes (NASDAQ:ALKS) with a Overweight and raises the price target from $65 to $68.
benzinga.com HC Wainwright & Co. Maintains Neutral on Alkermes, Raises Price Target to $50 HC Wainwright & Co. analyst Douglas Tsao maintains Alkermes (NASDAQ:ALKS) with a Neutral and raises the price target from $43 to $50.
seekingalpha.com Alkermes plc (ALKS) Q3 2026 Earnings Call Transcript Alkermes plc ( ALKS ) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Blair Jackson -…
marketbeat.com What Alkermes (ALKS) Said on Its Q3 Earnings Call Alkermes NASDAQ: ALKS reported third-quarter 2026 results marked by 31% year-over-year growth in proprietary product sales, while management highlighted continued investment in its orexin development…
zacks.com Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…
benzinga.com Alkermes Q3 2026 Earnings Call Transcript Alkermes (NASDAQ:ALKS) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
zacks.com Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates Alkermes (ALKS) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to earnings of $0.49 per share a year ago.
benzinga.com Alkermes Q3 EPS $0.09 Beats $(0.06) Estimate, Sales $480.100M Beat $463.606M Estimate Alkermes (NASDAQ:ALKS) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $(0.06) by 250 percent. This is a 81.63 percent decrease over earnings of $0.49 per…
benzinga.com Alkermes Affirms FY2026 Sales Guidance of $1.730B-$1.840B vs $1.822B Est Alkermes (NASDAQ:ALKS) affirms FY2026 sales outlook from $1.730 billion-$1.840 billion to $1.730 billion-$1.840 billion vs $1.822 billion estimate.
businesswire.com Alkermes plc Reports Third Quarter 2026 Financial Results DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended September 30, 2026. To view the detailed third quarter 2026 earnings press release and…
defenseworld.net Alkermes (NASDAQ:ALKS) vs. Vericel (NASDAQ:VCEL) Head to Head Contrast Vericel (NASDAQ: VCEL - Get Free Report) and Alkermes (NASDAQ: ALKS - Get Free Report) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares increased by 232.0% to $2.0 during Monday's pre-market session. The company's market cap stands at $62.2 million. AngioDynamics (NASDAQ:ANGO) shares…
businesswire.com Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD) DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive therapy to antidepressants in…
seekingalpha.com Alkermes Q3 Preview: The Pipeline Looks Strong, But Earnings Tell Another Story Alkermes is maintained at a 'Buy' with a $57 price target, driven by LUMRYZ's commercial momentum and a promising neuroscience pipeline. 3Q26 revenue is projected to rise 18% year-over-year but…
defenseworld.net Alkermes plc $ALKS Position Cut by Robeco Institutional Asset Management B.V. Robeco Institutional Asset Management B.V. trimmed its position in Alkermes plc (NASDAQ: ALKS) by 37.6% in the third quarter, according to the company in its most recent Form 13F filing with the…
gurufocus.com Alkermes to Report Third Quarter Financial Results on November 3, 2026 [url="]Alkermes plc[/url] (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday, November 3, 2026 to di
businesswire.com Alkermes to Report Third Quarter Financial Results on November 3, 2026 DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday, November 3, 2026 to discuss the company's third…
zacks.com Earnings Preview: Alkermes (ALKS) Q3 Earnings Expected to Decline Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
defenseworld.net Alkermes plc $ALKS Shares Sold by State of Alaska Department of Revenue State of Alaska Department of Revenue lessened its holdings in shares of Alkermes plc (NASDAQ: ALKS) by 43.6% during the undefined quarter, according to its most recent 13F filing with the SEC. The…
benzinga.com Alkermes Plans To Present Two Oral Presentations And Six Posters From Portfolio Of Sleep Medicine Research At ESRS 28th Congress, Sleep Europe 2026 — Data From Vibrance-1 Phase 2 Study Lancet Neurology Publication Evaluating Alixorexton in Narcolepsy Type 1 and Additional Data From Long-Term Extension Study in Narcolepsy Type 1 and Type 2 to be…
businesswire.com Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present two oral presentations and six posters from its industry-leading portfolio of sleep medicine research at the…
zacks.com 4 CNS Drug Stocks Worth Watching This World Mental Health Day AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.
seekingalpha.com Stock Picks From Seeking Alpha's September 2026 New Analysts Seeking Alpha welcomed 38 new analysts in September 2026. This article showcases their top picks and investment strategies. Highlighted companies include Qualcomm, Teladoc, and NewLake Capital…
defenseworld.net Critical Survey: Alkermes (NASDAQ:ALKS) and uniQure (NASDAQ:QURE) Alkermes (NASDAQ: ALKS - Get Free Report) and uniQure (NASDAQ: QURE - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the…
zacks.com LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now? LQDA's Yutrepia drives rapid growth, while ALKS benefits from a diversified portfolio, Lumryz and a broader pipeline.
seekingalpha.com Alkermes: Idiopathic Hypersomnia Could Expand Lumryz Into A Larger Growth And Margin Driver Alkermes is positioned for significant growth through LUMRYZ's potential expansion into idiopathic hypersomnia (IH), following positive Phase 3 results. LUMRYZ's IH indication could drive incremental…
benzinga.com Goldman Sachs Reinstates Neutral on Alkermes, Announces $50 Price Target Goldman Sachs analyst Andrea Newkirk reinstates Alkermes (NASDAQ:ALKS) with a Neutral and announces $50 price target.
zacks.com Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290 ALKS posts positive Phase I data for ALKS 7290, showing meaningful improvements in ADHD symptoms across dose levels in healthy volunteers and adults.- benzinga.com RBC Capital Reiterates Outperform on Alkermes, Maintains $56 Price Target RBC Capital analyst Leonid Timashev reiterates Alkermes (NASDAQ:ALKS) with a Outperform and maintains $56 price target.
benzinga.com Meta To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday Analysts upgraded Fifth Third to Buy and adjusted price targets for Exelon, Alaska Air, Fair Isaac, Meta, Alkermes, Twilio and Warner Bros. Discovery.- benzinga.com Baird Maintains Outperform on Alkermes, Raises Price Target to $61 Baird analyst Joel Beatty maintains Alkermes (NASDAQ:ALKS) with a Outperform and raises the price target from $58 to $61.
benzinga.com Alkermes Says Experimental Drug Could Open New Path in ADHD Treatment Alkermes reports positive Phase 1b data for ALKS 7290, showing clinical proof-of-concept for ADHD treatment. Learn key findings.- benzinga.com Alkermes Shares Topline Results From Phase 1 Proof-of-concept Study Evaluating ALKS 7290 For Attention-deficit Hyperactivity Disorder, Showing Meaningful Improvements In Patients Alkermes plc (NASDAQ:ALKS) today announced positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the company’s novel, investigational orexin 2 receptor (OX2R) agonist…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com JP Morgan Maintains Neutral on Alkermes, Raises Price Target to $61 JP Morgan analyst Jessica Fye maintains Alkermes (NASDAQ:ALKS) with a Neutral and raises the price target from $60 to $61.
benzinga.com Baird Maintains Outperform on Alkermes, Raises Price Target to $58 Baird analyst Joel Beatty maintains Alkermes (NASDAQ:ALKS) with a Outperform and raises the price target from $48 to $58.- benzinga.com Piper Sandler Reiterates Overweight on Alkermes, Raises Price Target to $65 Piper Sandler analyst David Amsellem reiterates Alkermes (NASDAQ:ALKS) with a Overweight and raises the price target from $43 to $65.
- benzinga.com Alkermes Affirms FY2026 Sales Guidance of $1.730B-$1.840B vs $1.812B Est Alkermes (NASDAQ:ALKS) affirms FY2026 sales outlook from $1.730 billion-$1.840 billion to $1.730 billion-$1.840 billion vs $1.812 billion estimate.
- benzinga.com Alkermes Q2 Sales $496.009M Beat $457.818M Estimate Alkermes (NASDAQ:ALKS) reported quarterly sales of $496.009 million which beat the analyst consensus estimate of $457.818 million by 8.34 percent. This is a 26.97 percent increase over sales of…
- benzinga.com Alkermes Terminates VIVITROL Authorized Generic Supply Agreement With Amneal Without Penalties On July 6, 2026, Alkermes plc (the "Company") and Amneal Pharmaceuticals LLC ("Amneal") terminated the previously disclosed Authorized Generic Product Supply Agreement entered into on September 9,…
benzinga.com This Liquidia Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday Top Wall Street analysts changed outlook on top stocks. See all changes including upgrades, downgrades, and initiations on analyst ratings page.
benzinga.com Micron To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday Top analysts changed outlook on top names: Intuit downgraded, Alkermes price target raised, Carmax target increased, Sezzle target up, Biogen target raised, Progressive target cut.
benzinga.com Venu Holding Pursues $80M Sale-Leaseback Transaction On Parking Garage Asset At Sunset Amphitheater In McKinney, Texas Company seeks to advance national expansion through innovative financing model; Founder personally invested in Company's first sale-leaseback transaction as part of an approximately $250 million…
benzinga.com Earnings Scheduled For May 5, 2026 
benzinga.com Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen for $41/share. Other gainers incl. Centessa, Annexon, Agios, Fulcrum, Scholar Rock, Alkermes, Wave…- benzinga.com Earnings Scheduled For February 25, 2026
benzinga.com Southern To Rally More Than 9%? Here Are 10 Top Analyst Forecasts For Friday 
benzinga.com Jim Cramer Says Sell Super Micro — Calls A European Chipmaker 'Cheap And Good' Jim Cramer recommended selling Super Micro Computer Inc. and doesn't recommend Alkermes plc. Huntington Bancshares is 'terrific.' Smith & Nephew plc should be sold. Cramer also recommends buying…
benzinga.com 10 Health Care Stocks With Whale Alerts In Today's Session